Your browser doesn't support javascript.
loading
In situ tissue pathology from spatially encoded mass spectrometry classifiers visualized in real time through augmented reality.
Woolman, Michael; Qiu, Jimmy; Kuzan-Fischer, Claudia M; Ferry, Isabelle; Dara, Delaram; Katz, Lauren; Daud, Fowad; Wu, Megan; Ventura, Manuela; Bernards, Nicholas; Chan, Harley; Fricke, Inga; Zaidi, Mark; Wouters, Brad G; Rutka, James T; Das, Sunit; Irish, Jonathan; Weersink, Robert; Ginsberg, Howard J; Jaffray, David A; Zarrine-Afsar, Arash.
Afiliação
  • Woolman M; Techna Institute for the Advancement of Technology for Health, University Health Network 100 College Street, Room 7-207, MaRS Building, Princess Margaret Cancer Research Tower, 7th floor (STTARR) Toronto ON M5G 1P5 Canada arash.zarrine.afsar@utoronto.ca +1-416-581-8473.
  • Qiu J; Department of Medical Biophysics, University of Toronto 101 College Street Toronto ON M5G 1L7 Canada.
  • Kuzan-Fischer CM; Techna Institute for the Advancement of Technology for Health, University Health Network 100 College Street, Room 7-207, MaRS Building, Princess Margaret Cancer Research Tower, 7th floor (STTARR) Toronto ON M5G 1P5 Canada arash.zarrine.afsar@utoronto.ca +1-416-581-8473.
  • Ferry I; Peter Gilgan Centre for Research and Learning, Hospital for Sick Children 686 Bay Street Toronto ON M5G 0A4 Canada.
  • Dara D; Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children Toronto ON M5G 1X8 Canada.
  • Katz L; Peter Gilgan Centre for Research and Learning, Hospital for Sick Children 686 Bay Street Toronto ON M5G 0A4 Canada.
  • Daud F; Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children Toronto ON M5G 1X8 Canada.
  • Wu M; Techna Institute for the Advancement of Technology for Health, University Health Network 100 College Street, Room 7-207, MaRS Building, Princess Margaret Cancer Research Tower, 7th floor (STTARR) Toronto ON M5G 1P5 Canada arash.zarrine.afsar@utoronto.ca +1-416-581-8473.
  • Ventura M; Techna Institute for the Advancement of Technology for Health, University Health Network 100 College Street, Room 7-207, MaRS Building, Princess Margaret Cancer Research Tower, 7th floor (STTARR) Toronto ON M5G 1P5 Canada arash.zarrine.afsar@utoronto.ca +1-416-581-8473.
  • Bernards N; Department of Medical Biophysics, University of Toronto 101 College Street Toronto ON M5G 1L7 Canada.
  • Chan H; Techna Institute for the Advancement of Technology for Health, University Health Network 100 College Street, Room 7-207, MaRS Building, Princess Margaret Cancer Research Tower, 7th floor (STTARR) Toronto ON M5G 1P5 Canada arash.zarrine.afsar@utoronto.ca +1-416-581-8473.
  • Fricke I; Department of Medical Biophysics, University of Toronto 101 College Street Toronto ON M5G 1L7 Canada.
  • Zaidi M; Peter Gilgan Centre for Research and Learning, Hospital for Sick Children 686 Bay Street Toronto ON M5G 0A4 Canada.
  • Wouters BG; Techna Institute for the Advancement of Technology for Health, University Health Network 100 College Street, Room 7-207, MaRS Building, Princess Margaret Cancer Research Tower, 7th floor (STTARR) Toronto ON M5G 1P5 Canada arash.zarrine.afsar@utoronto.ca +1-416-581-8473.
  • Rutka JT; Techna Institute for the Advancement of Technology for Health, University Health Network 100 College Street, Room 7-207, MaRS Building, Princess Margaret Cancer Research Tower, 7th floor (STTARR) Toronto ON M5G 1P5 Canada arash.zarrine.afsar@utoronto.ca +1-416-581-8473.
  • Das S; Techna Institute for the Advancement of Technology for Health, University Health Network 100 College Street, Room 7-207, MaRS Building, Princess Margaret Cancer Research Tower, 7th floor (STTARR) Toronto ON M5G 1P5 Canada arash.zarrine.afsar@utoronto.ca +1-416-581-8473.
  • Irish J; Techna Institute for the Advancement of Technology for Health, University Health Network 100 College Street, Room 7-207, MaRS Building, Princess Margaret Cancer Research Tower, 7th floor (STTARR) Toronto ON M5G 1P5 Canada arash.zarrine.afsar@utoronto.ca +1-416-581-8473.
  • Weersink R; Techna Institute for the Advancement of Technology for Health, University Health Network 100 College Street, Room 7-207, MaRS Building, Princess Margaret Cancer Research Tower, 7th floor (STTARR) Toronto ON M5G 1P5 Canada arash.zarrine.afsar@utoronto.ca +1-416-581-8473.
  • Ginsberg HJ; Techna Institute for the Advancement of Technology for Health, University Health Network 100 College Street, Room 7-207, MaRS Building, Princess Margaret Cancer Research Tower, 7th floor (STTARR) Toronto ON M5G 1P5 Canada arash.zarrine.afsar@utoronto.ca +1-416-581-8473.
  • Jaffray DA; Department of Medical Biophysics, University of Toronto 101 College Street Toronto ON M5G 1L7 Canada.
  • Zarrine-Afsar A; Peter Gilgan Centre for Research and Learning, Hospital for Sick Children 686 Bay Street Toronto ON M5G 0A4 Canada.
Chem Sci ; 11(33): 8723-8735, 2020 Jul 23.
Article em En | MEDLINE | ID: mdl-34123126
ABSTRACT
Integration between a hand-held mass spectrometry desorption probe based on picosecond infrared laser technology (PIRL-MS) and an optical surgical tracking system demonstrates in situ tissue pathology from point-sampled mass spectrometry data. Spatially encoded pathology classifications are displayed at the site of laser sampling as color-coded pixels in an augmented reality video feed of the surgical field of view. This is enabled by two-way communication between surgical navigation and mass spectrometry data analysis platforms through a custom-built interface. Performance of the system was evaluated using murine models of human cancers sampled in situ in the presence of body fluids with a technical pixel error of 1.0 ± 0.2 mm, suggesting a 84% or 92% (excluding one outlier) cancer type classification rate across different molecular models that distinguish cell-lines of each class of breast, brain, head and neck murine models. Further, through end-point immunohistochemical staining for DNA damage, cell death and neuronal viability, spatially encoded PIRL-MS sampling is shown to produce classifiable mass spectral data from living murine brain tissue, with levels of neuronal damage that are comparable to those induced by a surgical scalpel. This highlights the potential of spatially encoded PIRL-MS analysis for in vivo use during neurosurgical applications of cancer type determination or point-sampling in vivo tissue during tumor bed examination to assess cancer removal. The interface developed herein for the analysis and the display of spatially encoded PIRL-MS data can be adapted to other hand-held mass spectrometry analysis probes currently available.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article